These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 29499277

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
    Goyanes A, Hatton GB, Merchant HA, Basit AW.
    Int J Pharm; 2015 Apr 30; 484(1-2):103-8. PubMed ID: 25721685
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products.
    Schellekens RC, Stuurman FE, van der Weert FH, Kosterink JG, Frijlink HW.
    Eur J Pharm Sci; 2007 Jan 30; 30(1):15-20. PubMed ID: 17085024
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
    Jin C, Zhao C, Shen D, Dong W, Liu H, He Z.
    J Pharm Pharmacol; 2018 Feb 30; 70(2):250-258. PubMed ID: 29193077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Dissolution of mesalazine modified release tablets under standard and bio-relevant test conditions.
    Garbacz G, Rappen GM, Koziolek M, Weitschies W.
    J Pharm Pharmacol; 2015 Feb 30; 67(2):199-208. PubMed ID: 25557626
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
    Salehi N, Kuminek G, Al-Gousous J, Sperry DC, Greenwood DE, Waltz NM, Amidon GL, Ziff RM, Amidon GE.
    Mol Pharm; 2021 Sep 06; 18(9):3326-3341. PubMed ID: 34428047
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Carboxymethyl starch and lecithin complex as matrix for targeted drug delivery: I. Monolithic mesalamine forms for colon delivery.
    Mihaela Friciu M, Canh Le T, Ispas-Szabo P, Mateescu MA.
    Eur J Pharm Biopharm; 2013 Nov 06; 85(3 Pt A):521-30. PubMed ID: 23562535
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.